Assessment of reported adverse events after substitution between TNF alfa inhibitors biosimilars in the WHO pharmacovigilance database

被引：0

作者：

Orhon, P. ^{[1
]}

Robert, M. ^{[1
]}

Bernardeau, C. ^{[1
]}

Fusaroli, M. ^{[2
]}

Roustit, M. ^{[3
]}

Cracowski, J. L. ^{[1
]}

Khouri, C. ^{[1
]}

机构：

[1] Grenoble Alpes Univ Hosp, Pharmacovigilance Unit, Grenoble, France

[2] Dept Med & Surg Sci, Pharmacol Unit, Bologna, Italy

[3] Grenoble Alpes Univ Hosp, Clin Pharmacol Dept, Grenoble, France

来源：

FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2023年 / 37卷

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

PS-115

引用

页码：160 / 160

页数：1

共 50 条

[31] Safety of BRAF and MEK Inhibitors for Treatment of Metastatic melanoma: Analysis of the WHO Database of Adverse Events [J].

Rousset, M. ;

Gouverneur, A. ;

Arnaud, M. ;

Claraz, P. ;

Fourrier-Reglat, A. ;

Pariente, A. ;

Miremont-Salame, G. ;

Molimard, M. .

DRUG SAFETY, 2017, 40 (10) :972-973

[32] Adverse events following the use of immune checkpoint inhibitors: An analysis of the WHO VigiAccess database. [J].

Nikita, Nikita ;

Zinner, Ralph ;

Johnson, Jennifer Maria ;

Ghosh, Natasha ;

Wilson, Melissa ;

Lu-Yao, Grace L. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[33] Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database [J].

Kaur, Rimple Jeet ;

Charan, Jaykaran ;

Dutta, Siddhartha ;

Sharma, Paras ;

Bhardwaj, Pankaj ;

Sharma, Praveen ;

Lugova, Halyna ;

Krishnapillai, Ambigga ;

Islam, Salequl ;

Haque, Mainul ;

Misra, Sanjeev .

INFECTION AND DRUG RESISTANCE, 2020, 13 :4427-4438

[34] The Burden of Cardiac Adverse Events Associated With Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: A Large Pharmacovigilance Database Analysis [J].

Thakre, Anuj ;

Babbili, Akhilesh ;

Thotamgari, Sahith Reddy ;

Grewal, Udhayvir ;

Beedupalli, Kavitha ;

Dominic, Paari .

CIRCULATION, 2022, 146

[35] Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer: Observational retrospective study using the WHO pharmacovigilance database [J].

Dolladille, C. ;

Sassier, M. ;

Fedrizzi, S. ;

Chretien, B. ;

Milliez, P. ;

Lelong-Boulouard, V. ;

Alexandre, J. .

FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 :116-116

[36] Adverse events associated with acute pancreatitis caused by immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database [J].

Tong, Lihua ;

Yuan, Yanling ;

He, Wanming ;

Yang, Wen ;

Pan, Xingxi .

EXPERT OPINION ON DRUG SAFETY, 2025,

[37] Psychiatric adverse events during aripiprazole associated to other antipsychotics: a retrospective study of cases reported within the French PharmacoVigilance database [J].

Kheloufi, F. ;

Lepelley, M. ;

Montastruc, F. ;

Daveluy, A. ;

Rouby, F. ;

Drici, M. D. ;

Mallaret, M. ;

Micallef, J. .

FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 :72-73

[38] Multidimensional Assessment of Psychiatric Adverse Events Related to Proton Pump Inhibitors: A Real-World, Pharmacovigilance Study [J].

Zhan, Zhi-Qing ;

Li, Jia-Xin ;

Zhang, Wei-Gang ;

Huang, Shu-Yi ;

Fang, Xixi .

CNS NEUROSCIENCE & THERAPEUTICS, 2025, 31 (05)

[39] Classification of patient characteristics associated with reported adverse drug events to neuraminidase inhibitors: an applicability study of latent class analysis in pharmacovigilance [J].

Okada, Takuro ;

Hashiguchi, Masayuki ;

Hori, Satoko .

INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (06) :1332-1341

[40] Classification of patient characteristics associated with reported adverse drug events to neuraminidase inhibitors: an applicability study of latent class analysis in pharmacovigilance [J].

Takuro Okada ;

Masayuki Hashiguchi ;

Satoko Hori .

International Journal of Clinical Pharmacy, 2022, 44 :1332-1341

← 1 2 3 4 5 →